Related Experiment Video
Updated: Feb 18, 2026
Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
Published on: June 10, 2013
Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio
Todd Molfenter1, Carol Sherbeck, Sandy Starr
1Ohio Department of Mental Health and Addiction Services (OhioMHAS), Columbus, OH (TM, SS); University of Wisconsin-Madison, Center for Health Enhancement System Studies (CHESS), Madison, WI (CS); University of Wisconsin-Madison School of Education, Madison, WI (J-SK); UW-Center for Tobacco Research and Intervention, Madison, WI (MZ); Department of Family Medicine and Community Health, University of Wisconsin-Madison, Madison, WI (AQ); University of Wisconsin-Madison, Institute for Clinical and Translational Research, Madison, WI (NJ); Oregon Health & Science University, Portland, OR (DM).
Objective:
Few studies examine how payers address the need for improved access to pharmacotherapy for opioid use disorders and the influence of environmental variables on access to opioid agonist and antagonist medications.
Method:
The 52 Ohio Addiction Drug Abuse and Mental Health Services (ADAMHS) Boards that disburse funds for treatment services for the uninsured and underinsured were surveyed to assess coverage for opioid agonist and antagonist treatment medications. Analyses examined public health data on regional opioid addiction patterns, characteristics of the local health insurance market, and their associations with coverage for opioid addiction pharmacotherapy.
Results:
Most (70%) of the 44 participating ADAMHS Boards paid for opioid treatment medications. For payment policy, all Boards required behavioral therapy to be provided in conjunction with opioid agonist or opioid antagonist therapy, and 27% of the Boards limited length of a buprenorphine therapy regimen. Higher local opioid treatment admission rates were associated with higher rates of Board funding for opioid treatment pharmacotherapy. Environmental variables (eg, overdose fatality rates or the behaviors of private insurance payers) were not associated with ADAMHS support for opioid agonist or antagonist medication.
Conclusions:
The analysis highlights the policy preferences of these payers. Follow-up studies should examine the payer decision-making processes, preferences, and attitudes that affect support for pharmacotherapy for opioid dependence.
More Related Videos
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
07:05Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:25Analgesia and Pain Management
01:15Drug Abuse and Addiction: Pharmacological Phenomena
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
01:17Healthcare Agencies II
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources,...